Yuhan Operating Profit Up 51% on Lazertinib Royalties
Predicted impact: Medium
Operating profit up about 51% on royalties; preliminary Q3 earnings already reported in recent days.
000100 · KOSPI · ₩000100 · 유한양행
Predicted impact: Medium
Operating profit up about 51% on royalties; preliminary Q3 earnings already reported in recent days.
Predicted impact: Low
Q3 operating profit up 44%, but the same results were already reported in the last 14 days.
Predicted impact: Medium
Q3 operating profit up 50.8%; preliminary earnings already disclosed in the last 14 days.
Predicted impact: Low
Design award for a space; no financial relevance.
Predicted impact: Low
Technology research presented at a conference; no revenue or contract impact disclosed.
Predicted impact: Low
Predicted impact: Low
Clinical sequencing finding on side effects for an existing partnered drug; no financial size given.
Predicted impact: Low
Skincare line exclusive to Daiso; small consumer product launch with no size given.
Predicted impact: Low
Cosmetics line launch at Daiso; small product news.
Predicted impact: Low
Anniversary history book and target price changes; routine items.
Predicted impact: Low
Anniversary history book publication; no financial impact.
Predicted impact: Low
Founder monument unveiling is a ceremonial event with no financial impact.
Predicted impact: Low
Market wrap listing winners; repeats the Lilly Alzheimer's drug expectations already covered in recent days.
Predicted impact: Low
Market wrap listing winners; repeats the Lilly Alzheimer's drug expectations already covered in recent days.
Predicted impact: Medium
Royalty jump outlook is meaningful for Yuhan, but similar royalty and target news already covered in last 14 days.
Predicted impact: Low· Actual: +4.0% vs sector, volume 2.7× normal (5 trading days)
Broker target cut from valuation method change; an earlier broker cut already covered in recent days
Predicted impact: Low· Actual: +4.0% vs sector, volume 2.7× normal (5 trading days)
Target price cut with Q3 results in line with expectations; routine broker view.
Predicted impact: Medium· Actual: +4.0% vs sector, volume 2.7× normal (5 trading days)
Lazertinib sales above $300M quarterly; meaningful earnings driver, size vs revenue unclear.
Predicted impact: Medium· Actual: +10.2% vs sector, volume 2.7× normal (5 trading days)
Lazertinib quarterly sales above $300M is meaningful, but already reported in the last 14 days.
Predicted impact: Low· Actual: +10.2% vs sector, volume 2.7× normal (5 trading days)
Lazertinib combined sales above $300M were already reported in the past 14 days.
Also known as: Yuhan / 유한양행 / 000100 / KRX:000100
Source: KRX statistical information